Business mix
- The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive.
- Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima.
- The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands.
- In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand.
Current key questions
- Can the company's products, services, or pipeline expand adoption within drug manufacturers - general?
- How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
- Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
